From Joe Rogan to Hailey Bieber, NAD+ has become the longevity market’s hottest three-letter acronym, fueling a category projected to hit $20.17 billion by 2035 at an 8.34% CAGR, according to an SNS Insider report.
But for all the buzz, it’s the precursor (the building block cells used to make NAD+) that matters, according to Niagen Bioscience.
The company is launching at-home injection kits of pharmaceutical-grade Niagen through a new telehealth arm, so consumers can give themselves subcutaneous injections of Niacin Plus at home.
A quick science lesson: NAD+ is a coenzyme found in every living cell, responsible for energy production, DNA repair and cellular health. Levels decline with age by roughly 50% by the time most people hit their 50s. Replenishing NAD+, proponents say, can boost energy, stamina and metabolism, among other anti-aging benefits.
Consumers fill out an online medical intake form and have a consultation with a licensed provider. If eligible, they are prescribed the Niagen At-Home Injection Kit, $299, which is shipped to their home. Frequency and dosing will depend on individual needs.
“This launch expands access to Niagen through a clinician-directed telehealth model designed around quality, convenience and clinical oversight,” Niagen Bioscience CEO Rob Fried said.
It also follows a year of momentum for Niagen Bioscience, which reported 30% year over year net sales growth to $129.4 million in 2025.
Though NAD+ isn’t a peptide, Niagen Bioscience’s move arrives as longevity-seeking consumers have grown comfortable with injectables, normalized first by the GLP-1 boom and poised to expand further as the FDA weighs loosening restrictions on compounded peptides at an upcoming July advisory meeting.
